148
Participants
Start Date
November 30, 2020
Primary Completion Date
January 12, 2024
Study Completion Date
December 16, 2024
Allocetra-OTS
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
Placebo
Solution containing all excipients except for the Allocetra-OTS cells
Clinique Saint-Pierre, Brussels
Saint-Luc Hospital University, Brussels
CHU de Charleroi, Charleroi
Ziekenhuis Oost-Limburg, Genk
CHU d'Angers, Angers
Vendee Departmental Hospital Center, La Roche-sur-Yon
University Hospital of Limoges, Limoges
CHU de Montpellier, Montpellier
CHU de Nantes, Nantes
Bretonneau Hospital, Paris
Centre Hospitalier Victor Dupouy, Paris
Reims University Hospital Robert Debre, Reims
CHU de Rennes, Rennes
Strasbourg University Hospital, Strasbourg
Soroka Medical Center, Beersheba
Hillel Yaffe Medical Center, Hadera
Bnai Zion Medical Center, Haifa
Hadassah Ein Kerem Medical Center, Jerusalem
Beilinson Medical Center, Petah Tikva
Ziv Medical Center, Safed
Poriya Medical Center, Tiberias
Canisius Wilhelmina Hospital, Nijmegen
Radboud UMC, Nijmegen
Clinic Barcelona University Hospital, Barcelona
University Hospital Sagrat Cor, Barcelona
Vall d'Hebron, Barcelona
Getafe University Hospital, Getafe
Dr. Josep Trueta University Hospital, Girona
University Hospital Arnau de Vilanova of Lleida, Lleida
General University Hospital Gregorio Maranon, Madrid
University Hospital Joan XXIII of Tarragona, Tarragona
Lead Sponsor
Enlivex Therapeutics Ltd.
INDUSTRY